MINDMAZE
11.7.2022 15:02:07 CEST | Business Wire | Press release
MindMaze, a global pioneer in the development of neurotechnology, today confirms a new partnership with Alfa Romeo F1 Team ORLEN. Through this partnership, MindMaze will expand its groundbreaking research using its MindDrive brain technology platform to bring together advanced neuroscience, state-of-the-art technology, and engineering to boost safety and human performance in motorsport.
“We are delighted to be working closely with the Alfa Romeo F1 team to expand our partnership. Human performance is tested to the maximum in F1, which is why the research we are conducting with team ORLEN is so important. Our goal is not only to generate and study data that benefit human performance in motorsport, but also to inform the future of innovation for universal safety features across the entire automotive industry,” says MindMaze CEO Tej Tadi.
MindDrive’s brain technology platform is part of the company’s R&D innovation division— MindMaze Labs. The collaboration will include holistic research assessing both car and driver. The brain technology platform will specifically monitor human performance by capturing brain data, both on and off the racetrack. MindMaze’s F1 partnership represents a novel new field of study that underscores the company’s objective to transform brain health by decoding the brain and harnessing its ability to accelerate recovery from injury, learn, and adapt.
Frédéric Vasseur, Team Principal of Alfa Romeo F1 Team ORLEN, added, “Innovation is at the heart of everything we do in Formula One, so I’m proud to welcome MindMaze as a neurotechnology pioneer to our partner family. It is a company that has shown its research has real-world benefits, and I’m looking forward to combining our deep technical competencies to see what insights we can unlock together.”
MindMaze recently showcased the brain technology and its motorsport research at the Miami Grand Prix, where MindMaze was a founding partner. As part of the agreement, MindMaze will have brand sponsorship on the safety helmets of Alfa Romeo F1 Team ORLEN drivers Valtteri Bottas and Zhou Guanyu for the remainder of the 2022 F1 season.
MindMaze’s F1 programme is part of its growing portfolio of research in motorsport. Currently, it has a MindDrive-focused research project underway in the US with the Andretti Autosport Indycar team and its brain health ambassador, Romain Grosjean. Previous partners include F1’s McLaren and Haas teams.
About MindMaze
Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutics solutions for brain health and recovery. Its mission is to accelerate the brain’s ability to recover, learn, and adapt. The company has two core divisions— Healthcare and Labs— working collaboratively at the intersection of neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence. MindMaze Healthcare is advancing a universal platform for brain health with breakthrough solutions to some of the world’s most challenging problems in neurology, including stroke, Parkinson’s disease, and Alzheimer’s disease. MindMaze Labs, the company’s R&D innovation hub, is focused on the future of human computing— working across multiple industries to innovate and build the next generation of human-machine interfaces. The company has offices in Lausanne, Baltimore, London, Paris, and Mumbai. For more information, please visit www.mindmaze.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005379/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release
Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic
An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom